China (Mainland)
Paclitaxel CAS NO.33069-62-4
- Min.Order: 10 Gram
- Payment Terms: T/T,Other
- Product Details
Keywords
- Paclitaxel
- 33069-62-4,chemical
- research,C47H51NO14
Quick Details
- ProName: Paclitaxel
- CasNo: 33069-62-4
- Molecular Formula: C47H51NO14
- Appearance: Solid
- Application: Orally active estrogenic steroid. It w...
- DeliveryTime: 3days
- PackAge: in foil bag or customized
- Port: Tianjin xingang
- ProductionCapacity: 10 Kilogram/Week
- Purity: 99%
- Storage: Refrigerator
- Transportation: shipping by courier or by sea
- LimitNum: 10 Gram
Superiority
| Product Name: | Paclitaxel |
| Synonyms: | N-BENZYL-BETA-PHENYLISOSERINE ESTER;PACLITAXEL, TAXUS BREVIFOLIA;PACLITAXEL, TAXUS SPECIES;PACLITAXOL;PACLITAXEL;TAXOL(TM);taxol a;TAXOL EQUIVALENT |
| CAS: | 33069-62-4 |
| MF: | C47H51NO14 |
| MW: | 853.91 |
| EINECS: | 205-285-7 |
Details
| Paclitaxel Usage And Synthesis |
| Outline | Paclitaxel is a monomer diterpenoid compound extracted from bark of the natural plant, taxus. It is a kind of complex secondary metabolites and is currently known as the only kind drug that can promote microtubule polymerization and stabilize polymerized microtubules. Isotopic tracing has showed that paclitaxel only binds to polymerized microtubules without reacting with the non-polymerized tubulin dimer. Cells will accumulate large amount of microtubules inside cells after exposure to paclitaxel with the accumulation of these microtubules being able to interfere with various kinds of cellular functions, in particular, being able to stop cell division in the mitosis phase, blocking the normal cell division. ThroughⅡ-Ⅲ clinical study, paclitaxel is mainly applied to the treatment of ovarian and breast cancer and also has certain efficacy in the treatment of lung cancer, colorectal cancer, melanoma, head and neck cancer, lymphoma and brain tumors. |
| Indications | It has good efficacy in the treatment of ovarian cancer and refractory ovarian cancer already being resistant to existing platinum and breast cancer. It also has good prospect on the treatment of prostate cancer, head and neck cancer, esophageal cancer, germ cell tumors, endometrial carcinoma, lymphoma, bladder cancer, upper gastrointestinal cancer, small cell and non-small cell lung cancer. |
| Small history |
In 1963, American chemist MC Wani and Monre E. Wall had isolated for the first time of the paclitaxel crude extract from the bark and wood of the pacific yew growing in the western forest of United States. During the screening experiments of taxus, Wani and Wall have discovered that crude extracts of paclitaxel are of great activity to the in vitro culture of mouse tumor cells and began to separate this active ingredient. Owing to the very low levels of the active ingredient in the plant, it was not until 1971 that they, through the cooperation with Professor Andre T. McPhail in Duke University, used x-ray analysis and successfully determined the chemical structure of the active ingredient - a kind of tetracylicditerpene and named it as paclitaxel (Paclitaxel). In 1971, it had been found of paclitaxel in taxus and found a unique anticancer mechanism. In 1992 the US government assigned the patent to Bristol-Myers Squibb and the paclitaxel emerged. In 1994, Paclitaxel ranks first in the global sales of world anti-cancer drugs. In 2000, the Paclitaxel sales had reached ten billion (after that, due to the supply limit of raw materials, the sales amount got no further rise). In 2002, the central government had forbidden the cutting of wild yew and had encouraged artificial cultivation. In 2004, the patent of Bristol-Myers Squibb has expired. More and more global pharmaceutical companies have been involved in Paclitaxel production. In 2004, Huayuan started to conduct the taxus project and build direct paclitaxel-specific extraction factory with the aims of becoming the largest yew base in China and Asia. In 2005, the Central government again issued a document for the national census of yew resources to encourage planting. In 2005, this project received investment from individual investors. The above information is edited by the chemicalbook of Dai Xiongfeng. |